{"protocolSection":{"identificationModule":{"nctId":"NCT04962503","orgStudyIdInfo":{"id":"CUV801"},"organization":{"fullName":"Clinuvel Pharmaceuticals Limited","class":"INDUSTRY"},"briefTitle":"A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)","officialTitle":"A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS) Due to Distal [M2 Segment and Beyond] Arterial Large Vessel Occlusion (LVO) or Perforator Occlusion and Who Are Ineligible for Intravenous Thrombolysis (IVT) or Endovascular Thrombectomy (EVT)"},"statusModule":{"statusVerifiedDate":"2023-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-06-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-02-04","type":"ACTUAL"},"completionDateStruct":{"date":"2022-02-04","type":"ACTUAL"},"studyFirstSubmitDate":"2021-06-23","studyFirstSubmitQcDate":"2021-07-10","studyFirstPostDateStruct":{"date":"2021-07-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-02-03","resultsFirstSubmitQcDate":"2023-03-16","resultsFirstPostDateStruct":{"date":"2023-04-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-03-16","lastUpdatePostDateStruct":{"date":"2023-04-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Clinuvel Pharmaceuticals Limited","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The primary study objective is to assess the safety of afamelanotide while the secondary objective is to assess whether the therapy affects the size of the penumbra, by increasing blood flow, restoring oxygen supply to the brain, and reducing the amount of cerebral oedema (fluid) which is seen as a result of the stroke. Positive findings would indicate that the drug is able to support brain tissue-at-risk and provide overall neuroprotection and benefit to stroke patients."},"conditionsModule":{"conditions":["Arterial Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":6,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Afamelanotide","type":"EXPERIMENTAL","interventionNames":["Drug: Afamelanotide"]}],"interventions":[{"type":"DRUG","name":"Afamelanotide","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.","armGroupLabels":["Afamelanotide"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Changes in Volume of Infarct","timeFrame":"From Day 0 to Day 3 and Day 0 to Day 9"}],"secondaryOutcomes":[{"measure":"Changes of Neurological Function as Measured by the National Institutional Health Stroke Scale (NIHSS).","description":"0: No stroke symptoms 1-15: Mild to Moderate stroke 16-20: Moderate to severe stroke 21- 42: Severe stroke","timeFrame":"From baseline to Day 42"},{"measure":"Changes of Daily Activities as Measured by the Modified Rankin Scale (mRS)","description":"The mRS indicates the degree of disability or dependence in the daily activities of patients who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms (0) to death (+6).","timeFrame":"From baseline to Day 42"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects with a diagnosis of first AIS due to distal \\[M2 segment and beyond\\] occlusion or perforator occlusion\n* Perfusion abnormalities observed on Computed Tomography Perfusion (CTP)\n* Mild to moderate stroke severity\n* Pre-stroke mRS \\<4\n* Written informed consent obtained from patient and/or medical treatment decision maker prior to study-start (upon admission).\n\nExclusion Criteria:\n\n* Administration of intravenous thrombolytic therapy in distal occlusion as etiology of AIS\n* Intervention by endovascular thrombectomy (EVT)\n* Known allergy or anaphylaxis to adrenocorticotropic hormone (ACTH) or melanocortins or any of the excipients listed in the Investigator's Brochure\n* Any evidence of hepatic (defined as three times standard range) or renal impairment (defined as estimated glomerular filtration rate (eGFR) \\<50 mL/min/1.73 m²)\n* Any other medical condition which may interfere with the study protocol\n* Female who is pregnant (confirmed by positive serum beta human chorionic gonadotropin (β-HCG) pregnancy test prior to baseline) or lactating\n* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device) or a lifestyle excluding pregnancy\n* Unable to undergo MRI brain evaluation\n* Not suitable for trial participation according to judgment of the Principal Investigator (PI)\n* Patients starting afamelanotide 24 hours or more from ictus.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"The Alfred","city":"Melbourne","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"SCENESSE® (Afamelanotide 16mg)","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"SCENESSE® (Afamelanotide 16mg)","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76.0","lowerLimit":"50","upperLimit":"86"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race","categories":[{"title":"Caucasian","measurements":[{"groupId":"BG000","value":"5"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in Volume of Infarct","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"mL","timeFrame":"From Day 0 to Day 3 and Day 0 to Day 9","groups":[{"id":"OG000","title":"SCENESSE® (Afamelanotide 16mg)","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"}]}],"classes":[{"title":"Median change from baseline to Day 3","categories":[{"measurements":[{"groupId":"OG000","value":"9.97","lowerLimit":"1.71","upperLimit":"59.60"}]}]},{"title":"Median change from baseline to Day 9","categories":[{"measurements":[{"groupId":"OG000","value":"4.06","lowerLimit":"1.41","upperLimit":"57.60"}]}]}],"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.0313","pValueComment":"Change from baseline to Day 3","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.0625","pValueComment":"Change from baseline to Day 9","statisticalMethod":"Wilcoxon (Mann-Whitney)"}]},{"type":"SECONDARY","title":"Changes of Neurological Function as Measured by the National Institutional Health Stroke Scale (NIHSS).","description":"0: No stroke symptoms 1-15: Mild to Moderate stroke 16-20: Moderate to severe stroke 21- 42: Severe stroke","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Score on a scale","timeFrame":"From baseline to Day 42","groups":[{"id":"OG000","title":"SCENESSE® (Afamelanotide 16mg)","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","lowerLimit":"-8","upperLimit":"41"}]}]}]},{"type":"SECONDARY","title":"Changes of Daily Activities as Measured by the Modified Rankin Scale (mRS)","description":"The mRS indicates the degree of disability or dependence in the daily activities of patients who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms (0) to death (+6).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From baseline to Day 42","groups":[{"id":"OG000","title":"SCENESSE® (Afamelanotide 16mg)","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"}]}],"classes":[{"title":"Pre-stroke score 0","categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}]},{"title":"Pre-stroke score 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Pre-stroke score 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]},{"title":"Day 42 score 3","categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]},{"title":"Day 42 score 4","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Day 42 score 6","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All adverse events were monitored from baseline until 3 months after the end of treatment, up to 19 weeks.","description":"Patients were advised to report any adverse events to the PI. All adverse events were assessed as unrelated to SCENESSE® (afamelanotide 16 mg).","eventGroups":[{"id":"EG000","title":"SCENESSE® (Afamelanotide 16mg)","description":"Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.","deathsNumAffected":1,"deathsNumAtRisk":6,"seriousNumAffected":1,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6}],"seriousEvents":[{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":6}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Troponin increased","organSystem":"Investigations","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Hypervolaemia","organSystem":"Metabolism and nutrition disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]},{"term":"Delirium","organSystem":"Psychiatric disorders","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Clinical Operations Manager","organization":"CLINUVEL PHARMACEUTICALS LIMITED","email":"mail@clinuvel.com","phone":"Tel: +61 3 9660 4900"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2021-05-04","uploadDate":"2023-02-03T08:43","filename":"Prot_SAP_000.pdf","size":7733938}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-03-03","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Arterial Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000534526","term":"Afamelanotide"}],"ancestors":[{"id":"D000003879","term":"Dermatologic Agents"}],"browseLeaves":[{"id":"M287394","name":"Afamelanotide","asFound":"Hepatitis C Infection","relevance":"HIGH"},{"id":"M6764","name":"Dermatologic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Derm","name":"Dermatologic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}